

37. The method of claim 35 wherein said effective amount of said at least one carbon monoxide dependent guanylyl cyclase modulating purine derivative produces a treating concentration of at least 1 μ M.

38. The method of claim 35 wherein said neutropic growth factors are selected from the group consisting of nerve growth factor (NGF), fibroblast growth factor-2 (FGF-2), and neurotrophin-3 (NT-3).

AI 39. The method of claim 37 wherein said mammal is treated by orally administering said at least one carbon monoxide dependent guanylyl cyclase modulating purine derivative.

40. The method of claim 37 wherein said mammal is treated by injecting said at least one carbon monoxide dependent guanylyl cyclase modulating purine derivative.

Remarks

By way of this Preliminary Amendment, original claims 1-29 are cancelled and new claims 30-40 are added. Applicant respectfully requests examination of these new claims.

The Commissioner is authorized to charge any fee which may be required in connection with this Preliminary Amendment to deposit account No. 16-2230.

Respectfully submitted,

Dated: April 3, 2002


Louis C. Cullman
Registration No. 39,645

OPPENHEIMER WOLFF & DONNELLY LLP
840 Newport Center Drive, Suite 700
Newport Beach, CA 92660
Telephone: (949) 823-6000
Facsimile: (949) 823-6100